Summary：Hopeful Findings: Low-Dose Atropine Curbs Myopia in DIMS Non‑Responders A recent study published in

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Hopeful Findings: Low-Dose Atropine Curbs Myopia in DIMS Non‑Responders

A recent study published in *Scientific Reports* offers fresh optimism for children who do not respond to conventional defocus incorporated multiple segment (DIMS) lenses. Researchers report that low‑dose atropine eye drops significantly slowed myopia progression in this subgroup and were linked to measurable changes in pupillary light reflex kinetics. The findings suggest a complementary pharmacological approach that could expand treatment options for the growing number of youths affected by nearsightedness.

**Key Developments**
The trial enrolled 124 participants aged 8‑15 who had shown less than 0.25 diopter of axial length reduction after one year of DIMS lens wear. Half received 0.01 % atropine nightly, while the remainder continued with placebo drops. After 12 months, the atropine group exhibited a mean progression of 0.12 diopter versus 0.28 diopter in controls—a 57 % reduction. Additionally, objective pupillometry revealed a slower constriction velocity and prolonged redilation time in the treated eyes, indicating altered autonomic regulation of the iris. These physiological markers correlated with the refractive outcomes, providing a mechanistic hint that atropine may modulate retinal signaling pathways beyond simple muscarinic blockade.

**Industry Analysis**
Myopia management has become a lucrative niche, with spectacle‑based DIMS technology commanding premium pricing and atropine formulations traditionally reserved for higher concentrations. The demonstration that a ultra‑low dose can benefit DIMS non‑responders opens a potential cross‑sell opportunity for lens manufacturers